검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | anti-BCMA CAR-T |
Overview Company | Carbiogene Therapeutics Co. Ltd. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | CAR T cells (low CAR T-induced killing rate) |
MoA Biomarker | biomarkers to predict and identify factors associated with response and relapse |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 97.1% |
Clinical ORR | 96.6% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | anti-BCMA CAR-T |
Overview Company | Carbiogene Therapeutics Co. Ltd. |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | CAR T cells (low CAR T-induced killing rate) |
MoA Biomarker | biomarkers to predict and identify factors associated with response and relapse |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.. Chimeric antigen receptor T (CAR-T) cell therapy has become a standard of care for many hematological malignancies, and has significantly transformed treatment outcomes. However, CAR-T therapy is associated with specific toxicities, including infections. Although the anti-CD19 CAR-T risks… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 97.1% |
Clinical ORR | 96.6% |
Clinical PFS | NA |
Clinical OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03548207 |
Clinical Data Tier / Score | A · 64 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교